Stem Cell Therapy for Multiple Sclerosis Pipeline Analysis Report 2018 – ResearchAndMarkets.com

The “Stem
Cell Therapy for Multiple Sclerosis – A Pipeline Analysis report”
report has been added to ResearchAndMarkets.com’s

This pipeline analysis report offers detailed insights into the clinical
trials landscape of the stem cell therapy for multiple sclerosis
including molecules at different development stages. Moreover, the
report also offers information about the therapeutic assessment of the
pipeline molecules based on various segmentations including route of

The market research analysts have predicted that with the introduction
of mesenchymal stem cells therapy as one of the most promising
investigational approach to treat multiple sclerosis, the global
multiple sclerosis market will witness growth in the forthcoming years.
it has been observed that the American cryostem and celgene cellular
therapeutics have their stem cell therapy candidates for the treatment
of multiple sclerosis in phase I stage of development.

According to this pipeline analysis report, most of the companies have
not specified the type of multiple sclerosis their drugs are being
developed for. One of the Tier 1 companies Celgene cellular
therapeutics, is developing PDA-001 for RRMS as well as SPMS.

Companies covered

This pipeline analysis report provides a comprehensive analysis of the
companies that are actively involved in the development of stem cell
therapy molecules for the treatment of multiple sclerosis. In addition
to offering information on the various stages of molecules developed for
different indications, this pipeline analysis report also provides
information about the stem cell therapy molecules discontinued by

Some of the companies covered in this pipeline analysis report

Therapeutic assessment of the stem cell therapy for multiple
sclerosis by route of administration

According to our research experts, majority of stem cell therapy
candidates that are currently in the pipeline are being developed as
intravenous drugs. However, the RoA for several drugs that are in the
early development stages are not disclosed by companies.

For more information about this report visit https://www.researchandmarkets.com/research/zgj7x6/stem_cell_therapy?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005297/en/